Cutaneous Lesions that Mimic Infection in Transplant Patients

  • Ana CiureaEmail author
  • Sharon Hymes


Dermatologists are often called upon to evaluate skin lesions in organ transplant patients, especially when an infectious etiology is suspected. This section will review some of the non-infectious skin eruptions that mimic cutaneous infections. This chapter is intended to help the clinician generate a differential diagnosis when evaluating cutaneous lesions in organ transplant patients. Using the morphology of the primary lesion as a starting point, we then list the non-infectious diagnosis that could be considered and the infectious process it mimics.


Skin disorders Mimic infection Organ transplantation Immunosuppression Diagnostic clues 


  1. 1.
    Urano S, Kodama H, Kato K, Nogura K. Pyoderma gangrenosum with systemic involvement. J Dermatol. 1995;22(7):515–9.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Hurwitz RM, Haseman JH. The evolution of pyoderma gangrenosum. A clinicopathologic correlation. Am J Dermatopathol. 1993;15(1):28–33.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Callen JP. Pyoderma gangrenosum. Lancet. 1998;351(9102):581–5.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am. 2007;33(4):787–802, vi.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34(3):395–409; quiz 410–2.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Emmi L, Brugnolo F, Salvati G, et al. Immunopathological aspects of Behcet’s disease. Clin Exp Rheumatol. 1995;13(6):687–91.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet’s disease. Yonsei Med J. 2007;48(4):573–85.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Cohen PR, Kurzrock R. Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42(10):761–78.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    von den Driesch P. Sweet’s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31(4):535–56.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Cohen PR, Kurzrock R. Sweet’s syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol. 2000;18(3):265–82.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Kennedy C. The spectrum of inflammatory skin disease following jejuno-ileal bypass for morbid obesity. Br J Dernatol. 1981;105(4):425–35.CrossRefGoogle Scholar
  13. 13.
    Ely P. The bowel bypass syndrome: a response to bacterial peptidoglycans. J Am Acad Dermatol. 1980;2(6):473–87.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Revuz J, Valeyrie-Allanore L. Drug reactions. In: Bolognia J, Lorizzo JL, Rapini RP, Callen JP, Horn TD, Mancini AJ, et al., editors. Dermatology. Mosby: Elsevier; 2008. p. 301–20.Google Scholar
  15. 15.
    Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127(9):1333–8.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Ramdial PK, Naidoo DK. Drug-induced cutaneous pathology. J Clin Pathol. 2009;62(60):493–504.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    James WD. Clinical practice. Acne. N Engl J Med. 2005;352(14):1463–72.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Wnorowski AM, de Souza A, Chachoua A, Cohen DE. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol. 2012;51(2):223–32.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Nervi SJ, Schwartz RA, Dmochowski M. Eosinophilic pustular folliculitis: a 40 year retrospect. J Am Acad Dermatol. 2006;55(2):285–9.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Fraser SJ, Benton EC, Roddie PH, Krajewski AS, Goodlad JR. Eosinophilic folliculitis: an important differential diagnosis after allogeneic bone-marrow transplant. Clin Exp Dermatol. 2009;34(3):369–71.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Fukamachi S, Kabashima K, Sugita K, Kobayashi M, Tokura Y. Therapeutic effectiveness of various treatments for eosinophilic pustular folliculitis. Acta Derm Venereol. 2009;89(2):155–9.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Wenzel FG, Horn TD. Nonneoplastic disorders of the eccrine glands. J Am Acad Dermatol. 1998;38(1):1–17.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Mowad CM, McGinley KJ, Foglia A, Leyden JJ. The role of extracellular polysaccharide substance produced by Staphylococcus epidermidis in miliaria. J Am Acad Dermatol. 1995;33(5. Pt 1):729–33.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–9.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Cohen PR. Neutrophilic dermatoses occurring in oncology patients. Int J Dermatol. 2007;46(1):106–11.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14(2):212–6.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Kim BS, Kim WJ, Ko HC, Kim MB, Kim DW, Kim JM. Features of Staphylococcus aureus colonization in patients with nummular eczema. Br J Dermatol. 2013;168(3):658–60.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Lin SS, Tsai TH, Yang HH. Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis. Clin Exp Dermatol. 2009;34(4):528–30.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Wolf R, Oumeish OY, Parish LC. Intertriginous eruption. Clin Dermatol. 2011;29(2):173–9.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26(13):2085–92.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol. 2006;54(1):28–46.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Hill A, Hanson M, Bogle MA, Duvic M. Severe radiation dermatitis is related to Staphylococcus aureus. Am J Clin Oncol. 2004;27(4):361–3.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Johnson MA, Armstrong AW. Clinical and histologic diagnostic guidelines for psoriasis: a critical review. Clin Rev Allergy Immunol. 2013;44(2):166–72.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol. 2009;61(2):303–18.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, García-Fuentes M. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore). 1998;77(6):403–18. (review).Google Scholar
  36. 36.
    Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002;15(3):172–86.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Fischer AH, Morris DJ. Pathogenesis of calciphylaxis: study of three cases with literature review. Hum Pathol. 1995;26:1055.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Hussein MR, Ali HO, Abdulwahed SR, Argoby Y, Tobeigei FH. Calciphylaxis cutis: a case report and review of literature. Exp Mol Pathol. 2009;86(2):134–5.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Buckingham SC, Marshall GS, Schutze GE, et al. Clinical and laboratory features, hospital course, and outcome of Rocky Mountain spotted fever in children. J Pediatr. 2007;150(2):180–4, 184.e1.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Winkelmann RK. Panniculitis in connective tissue disease. Arch Dermatol. 1983;119:336.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Friedman PC, Husain S, Grossman ME. Nodular tuberculid in a patient with HIV. J Am Acad Dermatol. 2005;53(2. Suppl 1):S154–6.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Fernandes SS, Carvalho J, Leite S, Afonso M, Pinto J, Veloso R, et al. Erythema induratum and chronic hepatitis C infection. J Clin Virol. 2009;44(4):333–6.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Ugurel S, Lahaye T, Hildenbrand R, Glorer E, Reiter A, Hochhaus A, et al. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. Br J Dermatol. 2003;149(3):678–9.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006;354(24):2623.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Ball NJ, Adams SP, Marx LH, et al. Possible origin ofpancreatic fat necrosis as a septal panniculitis. J Am Acad Dermatol. 1996;34:362–4.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101(5):1012–23.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther. 2010;23:375–88.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Herouy Y, May AE, Pornschlegel G, Stetter C, Grenz H, Preissner KT, et al. Lipodermatosclerosis is characterized by elevated expression and activation on matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol. 1998;111:822–7.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Cantwell AR Jr, Martz W. Idiopathic bullae in diabetics. Bullosis diabeticorum. Arch Dermatol. 1967;96:42–4.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Larrey D. Memoires de Chirurgie Militaire et Campagnes. Paris: Smith and Buisson; 1812.Google Scholar
  51. 51.
    Groschel D, Gerstein AR, Rosenbaum JM. Skin lesions as a diagnostic aid in barbiturate poisoning. N Engl J Med. 1970;283:409–10.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Wenzel FG, Horn TD. Nonneoplastic disorders of the eccrine glands. J Am Acad Dermatol. 1998;38:1–17. quiz 8–20.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Herschthal D, Robinson MJ. Blisters of the skin in coma induced by amitriptyline and clorazepate dipotassium. Report of a case with underlying sweat gland necrosis. Arch Dermatol. 1979;115:499.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Varma AJ, Fisher BK, Sarin MK. Diazepam-induced coma with bullae and eccrine sweat gland necrosis. Arch Intern Med. 1977;137:1207–10.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Judge TG, Nisbet NH. Trophoneurotic blisters in elderly hemiplegics. Lancet. 1967;1:811–2.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Raymond LW. “Barbiturate blisters” in a case of severe hypoglycaemic coma. Lancet. 1972;2:764.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Mehregan DR, Daoud M, Rogers RS 3rd. Coma blisters in a patient with diabetic ketoacidosis. J Am Acad Dermatol. 1992;27:269–70.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9:316–21.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Teraki Y, Moriya N, Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol. 1994;145:550–60.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Ramdial PK, Naidoo DK. Drug-induced cutaneous pathology. J Clin Pathol. 2009;62:493–504.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2012;66:515 e1–e18.CrossRefGoogle Scholar
  63. 63.
    Schauder CS, Hymes SR, Rapini RP, Zipf TF. Vesicular graft-versus-host disease. Int J Dermatol. 1992;31:509–10.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Moreno JC, Valverde F, Martinez F, Velez A, Torres A, Fanego J, et al. Bullous scleroderma-like changes in chronic graft-versus-host disease. J Eur Acad Dermatol Venereol. 2003;17:200–3.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Hymes SR, Farmer ER, Burns WH, Morison WL, Tutschka PJ, Walters LL, et al. Bullous sclerodermalike changes in chronic graft-vs-host disease. Arch Dermatol. 1985;121:1189–92.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    McLaren GD, Muir WA, Kellermeyer RW. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci. 1983;19:205–66.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc. 1995;70:559–64.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Hogan D, Card RT, Ghadially R, McSheffrey JB, Lane P. Human immunodeficiency virus infection and porphyria cutanea tarda. J Am Acad Dermatol. 1989;20:17–20.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol. 2001;44:100–8.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Phung TL, Pipkin CA, Tahan SR, Chiu DS. Beta-lactam antibiotic-induced pseudoporphyria. J Am Acad Dermatol. 2004;51:S80–2.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Degiovanni CV, Darley CR. Pseudoporphyria occurring during a course of ciprofloxacin. Clin Exp Dermatol. 2008;33:109–10.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Kwong WT, Hsu S. Pseudoporphyria associated with voriconazole. J Drugs Dermatol. 2007;6:1042–4.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Epstein JH, Seibert JS. Porphyria-like cutaneous changes induced by tetracycline hydrochloride photosensitization. Arch Dermatol. 1976;112:661–6.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Alcalay J, David M, Ingber A, Hazaz B, Sandbank M. Bullous pemphigoid mimicking bullous erythema multiforme: an untoward side effect of penicillins. J Am Acad Dermatol. 1988;18:345–9.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Czechowicz RT, Reid CM, Warren LJ, Weightman W, Whitehead FJ. Bullous pemphigoid induced by cephalexin. Australas J Dermatol. 2001;42:132–5.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Kimyai-Asadi A, Usman A, Nousari HC. Ciprofloxacin-induced bullous pemphigoid. J Am Acad Dermatol. 2000;42:847.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999;340:1406–10.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998;16:393–7.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Yeh SW, Ahmed B, Sami N. Razzaque Ahmed A. Blistering disorders: diagnosis and treatment. Dermatol Ther. 2003;16:214–23.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Blenkinsopp WK, Haffenden GP, Fry L, Leonard JN. Histology of linear IgA disease, dermatitis herpetiformis, and bullous pemphigoid. Am J Dermatopathol. 1983;5:547–54.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Rosen LB, Frank BL, Rywlin AM. A characteristic vesiculobullous eruption in patients with chronic lymphocytic leukemia. J Am Acad Dermatol. 1986;15:943–50.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Ajithkumar K, George S, Babu PG. Abnormal insect bite reactions: a manifestation of immunosuppression of HIV infection? Indian J Dermatol Venereol Leprol. 2001;67:72–4.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Byrd JB, Woodard-Grice A, Stone E, Lucisano A, Schaefer H, Yu C, et al. Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy. 2010;65:1381–7.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Choy AC, Yarnold PR, Brown JE, Kayaloglou GT, Greenberger PA, Patterson R. Virus induced erythema multiforme and Stevens-Johnson syndrome. Allergy Proc. 1995;16:157–61.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019–24.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med. 2008;40:129–38.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    French LE, Prins C. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Bolognia J, Rapini R, editors. Dermatology. St. Louis, MO: Mosby Elsevier; 2008. p. 288.Google Scholar
  88. 88.
    Geria AN, Holcomb KZ, Scheinfeld NS. Necrolytic acral erythema: a review of the literature. Cutis. 2009;83:309–14.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Dabski K, Winkelmann RK. Generalized granuloma annulare: clinical and laboratory findings in 100 patients. J Am Acad Dermatol. 1989;20:39–47.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65:263–79. quiz 80CrossRefGoogle Scholar
  91. 91.
    Lott DG, Manz R, Koch C, Lorenz RR. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation. 2010;90:683–7.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Bangash HK, Colegio OR. Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients. Curr Treat Options Oncol. 2012;13(3):354–76.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–91.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Euvrard S, Kanitakis J, Pouteil-Noble C, Dureau G, Touraine JL, Faure M, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol. 1995;33:222–9.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Euvrard S, Chardonnet Y, Pouteil-Noble C, Kanitakis J, Chignol MC, Thivolet J, et al. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients. Cancer. 1993;72:2198–206.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer. 2005;104:1962–7.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009;125:1747–54.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol. 2010;146(3):300–4.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Scerri L, Williams HC, Allen BR. Dissecting cellulitis of the scalp: response to isotretinoin. Br J Dermatol. 1996;134:1105–8.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of DermatologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations